JP2015518857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518857A5 JP2015518857A5 JP2015513338A JP2015513338A JP2015518857A5 JP 2015518857 A5 JP2015518857 A5 JP 2015518857A5 JP 2015513338 A JP2015513338 A JP 2015513338A JP 2015513338 A JP2015513338 A JP 2015513338A JP 2015518857 A5 JP2015518857 A5 JP 2015518857A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- antigen
- domain
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 47
- 108090001005 Interleukin-6 Proteins 0.000 claims description 38
- 102000004889 Interleukin-6 Human genes 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 34
- 102000036639 antigens Human genes 0.000 claims description 34
- 108091007433 antigens Proteins 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 33
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 239000011800 void material Substances 0.000 claims description 10
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims description 5
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000003259 recombinant expression Methods 0.000 claims description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 4
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 241000282567 Macaca fascicularis Species 0.000 claims description 2
- 101100286715 Macaca fascicularis IL6 gene Proteins 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 230000009824 affinity maturation Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 102000052611 human IL6 Human genes 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 2
- 230000010474 transient expression Effects 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 2
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims 2
- 235000017274 Diospyros sandwicensis Nutrition 0.000 claims 1
- 101100029932 Drosophila melanogaster lama gene Proteins 0.000 claims 1
- 241000282838 Lama Species 0.000 claims 1
- 101100127662 Mus musculus Lama1 gene Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 241000282842 Lama glama Species 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650883P | 2012-05-23 | 2012-05-23 | |
| US61/650,883 | 2012-05-23 | ||
| US201261720102P | 2012-10-30 | 2012-10-30 | |
| US61/720,102 | 2012-10-30 | ||
| IBPCT/IB2012/056424 | 2012-11-14 | ||
| PCT/IB2012/056424 WO2013175276A1 (en) | 2012-05-23 | 2012-11-14 | Il-6 binding molecules |
| PCT/IB2013/054271 WO2013175427A1 (en) | 2012-05-23 | 2013-05-23 | Il-6 binding molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518857A JP2015518857A (ja) | 2015-07-06 |
| JP2015518857A5 true JP2015518857A5 (enExample) | 2016-07-07 |
| JP6410712B2 JP6410712B2 (ja) | 2018-10-24 |
Family
ID=47559582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513338A Active JP6410712B2 (ja) | 2012-05-23 | 2013-05-23 | Ｉｌ−６結合分子 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10183995B2 (enExample) |
| EP (1) | EP2852616A1 (enExample) |
| JP (1) | JP6410712B2 (enExample) |
| KR (1) | KR20150063311A (enExample) |
| CN (1) | CN103601806B (enExample) |
| AU (1) | AU2013264779B2 (enExample) |
| BR (1) | BR112014029219B1 (enExample) |
| CA (1) | CA2871148C (enExample) |
| CL (1) | CL2014003167A1 (enExample) |
| CO (1) | CO7240362A2 (enExample) |
| EC (1) | ECSP14029713A (enExample) |
| IL (1) | IL235134B (enExample) |
| MX (1) | MX360163B (enExample) |
| NZ (1) | NZ701370A (enExample) |
| PE (1) | PE20150335A1 (enExample) |
| RU (1) | RU2676078C2 (enExample) |
| WO (2) | WO2013175276A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018001853A2 (pt) | 2015-07-31 | 2018-09-25 | Astrazeneca Pharmaceuticals Lp | métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio |
| CN105194655A (zh) * | 2015-10-21 | 2015-12-30 | 胶州市人民中医医院 | 一种新生儿细菌感染性脑炎的治疗方法 |
| GB201611123D0 (en) * | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
| SG11201906852XA (en) | 2017-02-01 | 2019-08-27 | Univ Yale | Treatment of diuretic resistance |
| SG11202006157VA (en) | 2018-01-05 | 2020-07-29 | Corvidia Therapeutics Inc | Methods for treating il-6 mediated inflammation without immunosuppression |
| CN111153998B (zh) * | 2020-01-16 | 2022-06-24 | 佛山汉腾生物科技有限公司 | 抗ctla-4纳米抗体及其应用 |
| US20230236199A1 (en) * | 2020-04-23 | 2023-07-27 | Eli Lilly And Company | Subcutaneous absorption and bioavailability of antibodies |
| CN113150140B (zh) * | 2021-01-25 | 2022-11-04 | 山西农业大学 | 一种sox6二价纳米抗体及其应用 |
| EP4531867A1 (en) * | 2022-05-25 | 2025-04-09 | Ayuvis Research, Inc. | Novel immunodulating small molecules |
| CN117186222A (zh) * | 2022-05-31 | 2023-12-08 | 北京天广实生物技术股份有限公司 | Pd-l1结合分子及其用途 |
| CN119331091B (zh) * | 2024-11-06 | 2025-05-13 | 重庆探生科技有限公司 | 一种抗人白介素6的单克隆抗体及其应用 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US5460785A (en) | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| AU3968897A (en) | 1996-08-02 | 1998-02-25 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
| US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| PT1390535E (pt) | 2001-04-26 | 2010-10-04 | Amgen Mountain View Inc | Bibliotecas combinatórias de domínios monoméricos |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| MXPA04004671A (es) * | 2001-11-14 | 2005-08-25 | Johnson & Johnson | Anticuerpos anti-interleucina-6, composiciones, metodos y usos. |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| JP4459810B2 (ja) | 2002-08-14 | 2010-04-28 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| CA2499816C (en) | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| CA2552788C (en) | 2004-01-12 | 2013-09-24 | Applied Molecular Evolution, Inc. | Fc region variants |
| EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| JP2008500064A (ja) | 2004-05-21 | 2008-01-10 | ザ ユーエービー リサーチ ファウンデーション | 可変性リンパ球受容体、その関連ポリペプチドおよび核酸、ならびにその使用 |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| BRPI0510674A (pt) | 2004-07-15 | 2007-12-26 | Xencor Inc | variantes fc otimizadas |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| JO3058B1 (ar) | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
| EP1896503B1 (en) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
| RS53708B1 (sr) * | 2005-12-09 | 2015-04-30 | Ucb Pharma S.A. | Molekuli antitela koji poseduju specifičnost za humani il-6 |
| AR057227A1 (es) * | 2005-12-09 | 2007-11-21 | Centocor Inc | Metodo para usar antagonistas de il6 con inhibidores del proteasoma |
| WO2007104529A2 (en) * | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| CA2657763C (en) * | 2006-08-03 | 2016-05-31 | Vaccinex Inc. | Anti-il-6 monoclonal antibodies and uses thereof |
| TW200831528A (en) * | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| ES2721753T3 (es) | 2007-05-21 | 2019-08-05 | Alderbio Holdings Llc | Anticuerpos contra IL-6 y usos de los mismos |
| US8188235B2 (en) * | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| US8062866B2 (en) * | 2008-11-13 | 2011-11-22 | Femta Pharmaceuticals, Inc. | Humanized anti-IL-6 antibodies |
| BRPI1007005A2 (pt) | 2009-01-29 | 2016-03-22 | Medimmune Llc | anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6 |
| CA2777162A1 (en) | 2009-10-09 | 2011-04-14 | Anaphore, Inc. | Polypeptides that bind il-23r |
-
2012
- 2012-11-14 WO PCT/IB2012/056424 patent/WO2013175276A1/en not_active Ceased
-
2013
- 2013-05-23 RU RU2014152006A patent/RU2676078C2/ru active
- 2013-05-23 EP EP13734185.5A patent/EP2852616A1/en not_active Withdrawn
- 2013-05-23 JP JP2015513338A patent/JP6410712B2/ja active Active
- 2013-05-23 AU AU2013264779A patent/AU2013264779B2/en active Active
- 2013-05-23 PE PE2014001913A patent/PE20150335A1/es not_active Application Discontinuation
- 2013-05-23 CA CA2871148A patent/CA2871148C/en active Active
- 2013-05-23 NZ NZ701370A patent/NZ701370A/en unknown
- 2013-05-23 CN CN201310193693.6A patent/CN103601806B/zh active Active
- 2013-05-23 KR KR1020147031922A patent/KR20150063311A/ko not_active Ceased
- 2013-05-23 BR BR112014029219-1A patent/BR112014029219B1/pt active IP Right Grant
- 2013-05-23 WO PCT/IB2013/054271 patent/WO2013175427A1/en not_active Ceased
- 2013-05-23 US US14/403,135 patent/US10183995B2/en active Active
- 2013-05-23 MX MX2014014218A patent/MX360163B/es active IP Right Grant
-
2014
- 2014-10-19 IL IL235134A patent/IL235134B/en active IP Right Grant
- 2014-11-21 CL CL2014003167A patent/CL2014003167A1/es unknown
- 2014-11-24 CO CO14258229A patent/CO7240362A2/es unknown
- 2014-12-03 EC ECIEPI201429713A patent/ECSP14029713A/es unknown
-
2019
- 2019-01-03 US US16/239,321 patent/US11117959B2/en active Active
-
2021
- 2021-08-10 US US17/398,080 patent/US11827701B2/en active Active
-
2023
- 2023-10-23 US US18/492,526 patent/US20240158492A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015518857A5 (enExample) | ||
| KR101820699B1 (ko) | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| RU2014152006A (ru) | Молекулы, связывающие il-6 | |
| JP2012525829A5 (enExample) | ||
| AU2023266270B2 (en) | Engineered anti-il-2 antibodies | |
| TW201014602A (en) | Prostaglandin E2 binding proteins and uses thereof | |
| JP2013523184A5 (enExample) | ||
| JP2018510617A5 (enExample) | ||
| TW201641516A (zh) | 抗-ｉｌ-２３抗體 | |
| JP2013056885A5 (enExample) | ||
| CN110945027A (zh) | GARP-TGF-β抗体 | |
| KR20230132544A (ko) | 신규한 항-그렘린1 항체 | |
| JP2014530001A5 (enExample) | ||
| RU2019123112A (ru) | Анти-il-5 антитела | |
| TW201922798A (zh) | 靶向rankl的治療性抗體 | |
| JP2019509714A5 (enExample) | ||
| JP2010521139A5 (enExample) | ||
| JP2024517741A (ja) | 抗ｎｋｇ２ｄ抗体及びその使用 | |
| JP6529602B2 (ja) | 抗ｃｄ２０／抗ｂａｆｆ二重特異性抗体 | |
| TW202333788A (zh) | 一種抗ｔｎｆｒ２抗體藥物組合物 | |
| WO2025085352A1 (en) | Transferrin receptor binding proteins and uses thereof | |
| NZ791361B2 (en) | Engineered anti-il-2 antibodies | |
| WO2021051352A1 (zh) | 一种分离的抗原结合蛋白及其用途 | |
| WO2021051351A1 (zh) | 一种分离的抗原结合蛋白及其用途 |